Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Candesartan cilexetil and hydrochlorothiazide
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Blood Pressure, Blood Pressure, High, Drug Therapy
Eligibility Criteria
Inclusion Criteria:
- Confirmed diagnosis of essential hypertension.
- Has Systolic Blood Pressure between 150 mmHg and 200 mmHg AND Diastolic Blood Pressure between 110 mmHg and 120 mmHg.
- Has not received any antihypertensive treatment so far.
- Has a negative pregnancy test at baseline in females of childbearing potential. Male and female participants with reproductive potential must use an approved contraceptive method during study treatment evaluation
Exclusion Criteria:
- Has a known or suspected secondary hypertension or primary hyperaldosteronism.
- Has impaired renal function.
- Has severe hepatic impairment.
- Has bilateral renal artery stenosis, solitary kidney or post-renal transplant status.
- Has a history of myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention or cerebral accident (stroke or transient ischaemic attack) within the last 6 months.
- Has a diagnosis or suspicion of the following conditions: hypertrophic obstructive cardiomyopathy, angina pectoris, chronic heart failure, peripheral arterial occlusive disease, hypertensive retinopathy.
- Has hemodynamically relevant stenosis of the aortic or mitral valve.
- Has clinically relevant and refractory hypokalaemia or hyperkalaemia.
- Has uncorrected volume or sodium depletion.
- Has gout or relevant hyperuricaemia.
- Has a known intolerance/hypersensitivity to Candesartan cilexetil or Hydrochlorothiazide.
- Has a known galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
- Is taking psychotropic medication or is addicted to alcohol or drugs.
- Has participated in another trial of an investigational drug or a medical device within the last 30 days or is currently participating in another trial of an investigational drug or a medical device.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Candesartan QD + Hydrochlorothiazide QD
Arm Description
Outcomes
Primary Outcome Measures
Change from Baseline in Systolic Blood Pressure at Week 9.
The change between Systolic Blood Pressure (SBP) value collected at week 9 or final visit and SBP value collected at baseline
Change from Baseline in Diastolic Blood Pressure at Week 9.
The change between Diastolic Blood Pressure (DBP) value collected at week 9 or final visit and DBP value collected at baseline.
Secondary Outcome Measures
Percentage of subjects showing a decrease in SBP to less than 140 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 90 mmHg and/or a decrease of DBP by at least 10 mmHg.
Percentage of participants at week 9 or final visit showing a decrease in SBP to less than 140 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 90 mmHg and/or a decrease of DBP by at least 10 mmHg.
Percentage of subjects showing a decrease in SBP to less than 130 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 80 mmHg and/or a decrease of DBP by at least 10 mmHg.
Percentage of participants at week 9 or final visit showing a decrease in SBP to less than 130 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 80 mmHg and/or a decrease of DBP by at least 10 mmHg.
Change from Baseline in Pulse Rate at Week 9.
The change between Pulse Rate measured at week 9 and Pulse Rate measured at baseline.
Change from Baseline in Systolic Blood Pressure at Final Visit.
The change between the Systolic Blood Pressure value collected at week 9 or final visit and the Systolic Blood Pressure value collected at baseline.
Change in Baseline in Diastolic Blood Pressure at Final Visit.
The change between the Diastolic Blood Pressure value collected at week 9 or final visit and the Diastolic Blood Pressure value collected at baseline.
Change from Baseline in Pulse Rate at Final Visit.
The change between Pulse Rate measured at week 9 or final visit and the Pulse Rate measured at baseline.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01012479
Brief Title
Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
Official Title
Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
July 2010
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
May 2010 (Actual)
Study Completion Date
June 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Takeda
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to see if Candesartan, once daily (QD), added with Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential hypertension.
Detailed Description
Medical data show a link between blood pressure and the risk of heart disease (cardiovascular disease) such as stroke and heart attack. Clinical trials have shown that lowering blood pressure in patients with high blood pressure (hypertension) reduces the number of cardiovascular events.
Many people still have untreated hypertension. There are many reasons why target blood pressure is not reached. One is that most patients need more than one antihypertensive drug in order to lower high blood pressure. Other reasons include poor patient compliance with taking their drugs.
Combining drugs that lower high blood pressure and have similar ways of working in the body may help high blood pressure and lower the risk for medication-related side effects. One of several drug combinations recommended for the treatment of high blood pressure is an angiotensin receptor blocker and a thiazide diuretic. Guidelines also note that combination tablets may improve patient compliance with taking their drugs.
Candesartan is an angiotensin type-1 receptor blocker. Hydrochlorothiazide is a diuretic with blood pressure-lowering effect. This study will combine both of these drugs in one pill and see how it works in people taking part in this study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Blood Pressure, Blood Pressure, High, Drug Therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
107 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Candesartan QD + Hydrochlorothiazide QD
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Candesartan cilexetil and hydrochlorothiazide
Other Intervention Name(s)
Blopress, Atacand®, Amias, Ratacand, Kenzen, Blopressid
Intervention Description
Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
Primary Outcome Measure Information:
Title
Change from Baseline in Systolic Blood Pressure at Week 9.
Description
The change between Systolic Blood Pressure (SBP) value collected at week 9 or final visit and SBP value collected at baseline
Time Frame
Baseline and Week 9.
Title
Change from Baseline in Diastolic Blood Pressure at Week 9.
Description
The change between Diastolic Blood Pressure (DBP) value collected at week 9 or final visit and DBP value collected at baseline.
Time Frame
Baseline and Week 9.
Secondary Outcome Measure Information:
Title
Percentage of subjects showing a decrease in SBP to less than 140 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 90 mmHg and/or a decrease of DBP by at least 10 mmHg.
Description
Percentage of participants at week 9 or final visit showing a decrease in SBP to less than 140 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 90 mmHg and/or a decrease of DBP by at least 10 mmHg.
Time Frame
Week 9.
Title
Percentage of subjects showing a decrease in SBP to less than 130 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 80 mmHg and/or a decrease of DBP by at least 10 mmHg.
Description
Percentage of participants at week 9 or final visit showing a decrease in SBP to less than 130 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 80 mmHg and/or a decrease of DBP by at least 10 mmHg.
Time Frame
Week 9.
Title
Change from Baseline in Pulse Rate at Week 9.
Description
The change between Pulse Rate measured at week 9 and Pulse Rate measured at baseline.
Time Frame
Baseline and Week 9.
Title
Change from Baseline in Systolic Blood Pressure at Final Visit.
Description
The change between the Systolic Blood Pressure value collected at week 9 or final visit and the Systolic Blood Pressure value collected at baseline.
Time Frame
Baseline and Final Visit (up to Week 9)
Title
Change in Baseline in Diastolic Blood Pressure at Final Visit.
Description
The change between the Diastolic Blood Pressure value collected at week 9 or final visit and the Diastolic Blood Pressure value collected at baseline.
Time Frame
Baseline and Final Visit (up to Week 9)
Title
Change from Baseline in Pulse Rate at Final Visit.
Description
The change between Pulse Rate measured at week 9 or final visit and the Pulse Rate measured at baseline.
Time Frame
Baseline and Final Visit (up to Week 9)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Confirmed diagnosis of essential hypertension.
Has Systolic Blood Pressure between 150 mmHg and 200 mmHg AND Diastolic Blood Pressure between 110 mmHg and 120 mmHg.
Has not received any antihypertensive treatment so far.
Has a negative pregnancy test at baseline in females of childbearing potential. Male and female participants with reproductive potential must use an approved contraceptive method during study treatment evaluation
Exclusion Criteria:
Has a known or suspected secondary hypertension or primary hyperaldosteronism.
Has impaired renal function.
Has severe hepatic impairment.
Has bilateral renal artery stenosis, solitary kidney or post-renal transplant status.
Has a history of myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention or cerebral accident (stroke or transient ischaemic attack) within the last 6 months.
Has a diagnosis or suspicion of the following conditions: hypertrophic obstructive cardiomyopathy, angina pectoris, chronic heart failure, peripheral arterial occlusive disease, hypertensive retinopathy.
Has hemodynamically relevant stenosis of the aortic or mitral valve.
Has clinically relevant and refractory hypokalaemia or hyperkalaemia.
Has uncorrected volume or sodium depletion.
Has gout or relevant hyperuricaemia.
Has a known intolerance/hypersensitivity to Candesartan cilexetil or Hydrochlorothiazide.
Has a known galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
Is taking psychotropic medication or is addicted to alcohol or drugs.
Has participated in another trial of an investigational drug or a medical device within the last 30 days or is currently participating in another trial of an investigational drug or a medical device.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Takeda Pharma GmbH (Germany)
Official's Role
Study Director
Facility Information:
City
Berlin
Country
Germany
City
Blankenhain
Country
Germany
City
Dortmund
Country
Germany
City
Hamburg
Country
Germany
City
Köthen
Country
Germany
City
Löhne
Country
Germany
City
Nürnberg
Country
Germany
City
Remscheid
Country
Germany
City
Rodgau
Country
Germany
City
Stockach
Country
Germany
City
Wardenburg
Country
Germany
City
Weinheim
Country
Germany
City
Ivano-Frankivsk
Country
Ukraine
City
Kharkiv
Country
Ukraine
City
Kiev
Country
Ukraine
City
Lviv
Country
Ukraine
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
We'll reach out to this number within 24 hrs